Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023
Portfolio Pulse from Benzinga Newsdesk
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) announced that results from a Phase 2 etripamil study will be presented at the American Heart Association (AHA) Scientific Sessions 2023. The study evaluated etripamil in emergency department patients with atrial fibrillation with rapid ventricular rate (AFib-RVR).
September 27, 2023 | 11:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Milestone Pharmaceuticals' announcement of presenting their Phase 2 etripamil study results at the AHA Scientific Sessions 2023 could potentially boost investor confidence in the company's research and development capabilities.
The announcement of the presentation of the Phase 2 etripamil study results at a prestigious event like the AHA Scientific Sessions 2023 indicates that the company's research is being recognized by the scientific community. This could potentially boost investor confidence in the company's research and development capabilities, leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100